Jonathan Hurov, Ph.D.

Executive Vice President, Discovery Biology

Jonathan Hurov brings to Parabilis Medicines an impressive track record in oncology drug discovery and platform biology. With multiple patents, publications and extensive experience, he leads discovery biology, proteomics and biochemistry.

Jonathan’s previous industry experience includes being one the first employees hired at Cygnal Therapeutics, where he oversaw the platform build and all of the company’s early research. Over a period of four years, he built a team that broke new ground at the intersection of neurobiology and cancer biology, and advanced two novel programs through preclinical development. He was also instrumental in helping the company achieve two series of funding. Prior to Cygnal, Jonathan was also an early employee of Agios Pharmaceuticals, where he spent more than seven years with the company. He held multiple roles in target ID and validation, drug discovery and translational biology, with a therapeutic focus on cancer metabolism.

Jonathan holds a B.Sc. in biochemistry from the University of Victoria in British Columbia, Canada and a Ph.D. in biomedical sciences from Washington University in St. Louis. After his time in St. Louis, Jonathan pursued a postdoctoral fellowship at Harvard Medical School, where he studied the role of lipid and protein kinases in the regulation of cancer cell growth and metabolism.